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We analyzed the antimycobacterial activity of the hexane extract of rhizomes from Aristolochia elegans. Some compounds of
this extract were puriﬁed and tested against a group of drug-resistant Mycobacterium tuberculosis strains. We also evaluated
their antiprotozoal activities. The hexane extract was active against M. tuberculosis H37Rv at a MIC = 100μgmL −1; the pure
compounds eupomatenoid-1, fargesin, and (8R,8 R,9R)-cubebin were active against M. tuberculosis H37Rv (MIC = 50μgmL −1),
while fargesin presented activity against three monoresistant strains of M. tuberculosis H37Rv and a MDR clinical isolate of M.
tuberculosis (MIC < 50μgmL −1). Both the extract and eupomatenoid-1 were very active against E. histolytica and G. lamblia
(IC50 < 0.624μgmL −1); in contrast, fargesin and (8R,8 R,9R)-cubebin were moderately active (IC50 < 275μgmL −1). In this
context, two compounds responsible for the antimycobacterial presented by A. elegans are fargesin and cubebin, although others
may exert this activity also. In addition to the antimycobacterial activity, the hexane extract has important activity against E.
histolytica and G. lamblia, and eupomatenoid-1 is one of the compounds responsible for the antiparasite activity.
1.Introduction
Aristolochia elegans Mast (Aristolochiaceae) syn. A. littoralis
is commonly known as guaco, duck ﬂower, or elephant foot
and is a perennial shrub cultivated as an ornamental plant in
several parts of the world [1, 2]. The genus Aristolochia com-
prises ca. 400 species and is distributed in wide areas from
tropical to template zones [3]. On the American continent,
it is found from the south of the USA, throughout Mexico,
the Caribbean, and Central America and as far as Argentina
[4, 5]. A. elegans has been employed as an expectorant,
an antitussive, an antiasthmatic, an analgesic, an antihis-
tamine, and a detoxicant agent [3]. Moreover, A. elegans is
utilized as an antidote against snake bites and toothache, as
a purgative, an insecticide, and as an antispasmodic [6]. In
Mexican traditional medicine, this plant is used as antimi-
crobial, antitumoral, antidiarrheal, antipyretic, emmenagic
agent, and anti-snake venom and for the treatment of
scorpion poisoning [6, 7]. Alkaloids, lignans, neolignans,
monoterpenoids, diterpenoids, sesquiterpenoids, tetralones,
isoquinolines, porphyrins, biphenyl ethers, aristolactolac-
tams, and aristolochic acid dimers have been isolated from
the organic extracts or essential oil of leaves, stems, and
r o o t so ft h i ss p e c i e s[ 2–5] .T h eh e x a n e( H e x )a n dm e t h a n o l
(MeOH) extracts of A. elegans have proven to be moderately
active against the venom of Centruroides limpidus limpidus,2 Evidence-Based Complementary and Alternative Medicine
and the mixture of hexanic extracts from A. elegans and Bou-
vardia ternifolia has improved their inhibitory eﬀects up to
70% [6]. On the other hand, A. elegans ethanolic (EtOH)
extract exhibited antimitotic and antiviral activities [3, 8]. In
a preliminary study, we focused on the analysis the activity of
the Hex and MeOH extract (at 100μgmL −1) from the leaves,
seeds, and rhizomes of A. elegans against M. tuberculosis
H37Rv by radiorespirometric Bactec 460 assay. The Hex
extract from leaves and seeds reduced the mycobacterium




major compounds found in the Hex extract of A. elegans-
rhizome.
In this paper, the isolation of (8R,8 R,9R)-cubebin, far-
gesin, and eupomatenoid-1 from the active Hex extract of
A. elegans rhizome is described and their antimycobacterial
activity against four monoresistant and two MDR M.
tuberculosis strains is demonstrated. In addition, the activity
of the isolated compounds was tested against the anaerobic
protozoa: Entamoeba histolytica and Giardia lamblia.
2. Methods
2.1. General Experimental Procedures. The chemical charac-
terization of the isolated compounds was determined by 1H-
NMR (Bruker-Avance F, 300MHz) and 13C-NMR (Variant
Unity, 75.4MHz) using Tetramethylsilane as an internal
standard in CDCl3. Electron impact-mass spectra (EI-MS)
were obtained on a Jeol AX-505 HA mass spectrometer
at 70eV. Melting points (m.p.) were determined with a
Fisher-Johns apparatus and are uncorrected. Open Column
chromatography (CC) was carried out by using silica gel
60 GF254 (70–230 mesh, Merck) as a stationary phase, and
silicagel60F254 precoatedaluminumplates(0.2mm,Merck)
were employed for analytical and preparative Thin Layer
Chromatography (TLC) analysis. Hex, chloroform (CHCl3),
and MeOH were obtained from Mallinckrodt and J. T. Baker.
The spots were visualized by spraying it with a 10% solu-
tion of aqueous H2SO4 followed by heating at 100◦C. High
Performance Liquid Chromatography (HPLC) analyses were
carried out with a Waters 600 system controller connected to
a photodiode array detector 996, which was programmed to
collect data from 220–380nm at 2.4-nm resolutions. Control
of equipment, data acquisition, and processing and the man-
agement of chromatographic information were performed
by Millennium 32 software program (Waters). Analyses were
accomplished on a Spherisorb S100DS2 RP column (4.6 ×
250mm, 10-μm particle size, Waters). The mobile phase
comprised an isocratic MeOH system (HPLC grade, J. T.
Baker), except for eupomatenoid-1 whose mobile phase
was composed of acetonitrile/formic acid 98:2 (both HPLC
grade, J. T. Baker). The ﬂow rate was maintained constant at
0.3mLmin−1 for 30min. Samples were solubilized in MeOH
at 1mgmL−1,a n dav o l u m eo f2 0μL was injected.
2.2. Plant Material. Aristolochia elegans-rhizome was col-
lected in Miahuatlan, Oaxaca State, Mexico, in November
2006. The plant was botanically identiﬁed by Abigail Aguilar,
M.Sc., and a voucher specimen was deposited at the Herbar-
ium of the Instituto Mexicano del Seguro Social, Mexico
(IMSSM) with code number 16080.
2.3. Extraction and Isolation. Powdered air-dried rhizome
(530g) was macerated (3 × 48h) with 5L Hex at room
temperature. The extract obtained was ﬁltered and vacuum
concentrated to yield 37g of the crude extract. The Hex
extract (35g) was subjected to CC in silica gel (150g) and
was eluted with Hex:CHCl3 (100→0) and CHCl3 :MeOH
(100→0), and 171 fractions of 125mL each were obtained.
Primary fractions (F1–F15) were combined according to a
TLC analysis as follows: F1 (69mg); F2 (10mg); F3 (18mg);
F4 (92mg); F5 (69mg); F6 (149mg); F7 (115mg); F8
(434mg); F9 (258mg); F10 (322mg); F11 (1,816mg); F12
(1,218mg); F13 (669mg); F14 (14,109mg); F15 (5,870mg).
Fraction F5–F10 was submitted to preparative TLC em-
ploying Hex:CHCl3 70:30 as an elution system; after this
procedure, 53.5mg of eupomatenoid-1 (1) was obtained
with Rf = 0.13. On the other hand, primary fraction F14
(13g) was subjected to repeated CC, utilizing silica gel
(75g) with solvent gradients of Hex:CHCl3(100 to 0) and
CHCl3 :MeOH (100 to 0). This process yielded 13 secondary
fractions (FA-FM) of 150mL each as follows: FA (9mg); FB
(11mg); FC (69mg); FD (10mg); FE (304mg); FF (819mg);
FG (1,351mg); FH (794mg); FI (3,239mg); FJ (384mg); FK
(2,599mg); FL (1,489mg); FM (2,029 mg).
From secondary fractions FG and FH (2g), fargesin (2)
(607mg) was isolated after successive CC and the recrys-
tallization procedure with Hex. From secondary fraction FI
(3g), a mixture of fargesin and (8R,8 R,9R)-cubebin (2 and
3)wasobtainedandaftersuccessiveCCandpreparativeTLC,
835.9mg of 3 and 507.7mg of 2 were puriﬁed.
Eupomatenoid-1 (1) was obtained as white crystalline
needles with an m.p. of 157-158◦C (lit, 154–156◦C), soluble
in CHCl3, with a retention time (Rt) = 13.09min at 220 and
280nm, and using a Hex:CHCl3 1:1 system, it yielded a
Retention factor (Rf) = 0.13. IR (KBr): 2,937, 2,849, 1,725,
1,604,1,493,1,448,1,250,1,142,and1,041cm−1.IE-MS:m/z
(rel. int) 322 (100), 295 (10), 291 (10), 202 (15), 121 (6), 77
(5), and 46 (15). 1H-NMR (300MHz, CDCl3): 7.03 (1H, d,
J = 1.5Hz, H-4), 6.82 (1H, d, J = 1.5 Hz, H-6), 7.1 (1H, d,
J = 2Hz, H-2 ), 7.25–7.32 (1H, d, J = 8.2Hz, H-5 ), 6.98
(1H, dd, J = 8.2 and 0.6Hz, H-6 ), 6.0 (2H, s, OCH2O), 4.03
(3H,s,OCH3),2.40(3H,s,3-CH3),6.5(1H,dd, J =15.6and
1.5Hz,Hα),6.15–6.27(1H,dq,J =15.6and6.6Hz,Hβ),and
1.91 (3H, dd, J = 6.6 and 1.5Hz, H-γ). 13C NMR (75.4MHz,
CDCl3): 151.14 (C-2), 110.5 (C-3), 133.0 (C-3a), 133.6 (C-
5), 109.2 (C-4), 104.4 (C-6), 177.8 (C-7), 142.1 (C-7a), 123.7
(C-1 ),109.4(C-2 ),147.4(C-3 ),147.9(C-4 ),114.4(C-5 ),
120.6 (C-6 ), 101.2 (OCH2O), 56.2 (OCH3), 9.6 (3-CH3),
131.4 (C-α), 124.4 (C-β), and 18.4 (C-γ).
Fargesin (2) was obtained as a white powder with an
m.p. of 136–139◦C (lit, 137–139◦C and 133-134◦C), soluble
in CHCl3,w i t ha nRt = 13.52min. at 220 and280nm,
and showing Rf = 0.56 with a Hex:EtOAc 1:1 system. IR
(KBr): 2,960, 2,870, 2,841, 1,606, 1,592, 1,512, 1,492, and
1,240cm−1.I E - M S :m/z (rel. int) 370 [M+ (100)], 339 (12),Evidence-Based Complementary and Alternative Medicine 3
177 (40), 161 (40), 151 (15), 150 (10), 149 (45), 135 (30),
and 122 (15). 1H-NMR (300MHz, CDCl3): 6.76–6.9 (6H,
m, H-2,5,6,2 ,5  and 6 ), 4.73 (2H, d, J = 4.0 Hz, H-7α and
7 α), 4.25 (2H, m, H-9α and 9β)3 . 0 8( 1 H ,m ,8a n d8  ), 3.86
(2H, m, H-9 α and 9 β), 5.95 (2H, s, OCH2O), 3.89 (3H,
s, OCH3), and 3.86 (3H, s, OCH3). 13C NMR (75.4MHz,
CDCl3): 101.0 (OCH2O), 133.6 (C-1), 135.1 (C-1 ), 106.5
(C-2), 108.2 (C-2 ), 109.3 (C-5), 111.1 (C-5 ), 118.2 (C-6),
119.3 (C-6 ), 147.1 (C-3), 148.0 (C-3 ), 148.7 (C-4), 149.2
(C-4 ), 85.3 (7), 85.7 (C-7 ), 54.3 (C-8), 71.7 (C-9), 71.7 (C-
9 ), 54.2 (C-8 ) ,a n d5 6 . 0( 2O C H 3).
(8R,8 R,9R)-cubebin (3) was obtained as white needles
with an m.p. of 127-128◦C, soluble in CHCl3,w i t ha nRt =
14.85min. at 280nm, and an Rf = 0.37 using a CHCl3
system. IR (KBr): 3,365, 2,896, 1,611, 1,492, 1,441, 1,243,
and 1,037cm−1.I E - M S :m/z (rel. int) 356 (30), 338 (30), 203
(40), 202 (15), 135 (100), and 81 (70). 1H-NMR (300MHz,
CDCl3): 6.49–6.73 (6H, m, H-2,5,6,2 ,5  and 6 ), 5.92 and
5.91 (4H, s, 2 OCH2O), 5.22 (1H, d, J = 1.5Hz, H-9α), 4.1
(1H, dd, J = 8.7, 6.9Hz, H-9 α), 3.78 (1H, dd, J = 8.7, 7.2Hz,
H-9 β), 2.14 (2H, m, 8  and 8), 2.43 (2H, m, H-7α and 7 α),
2.75 (1H, m, H-7β), and 2.60 (1H, m, H-7 β). 13CN M R
(75.4MHz, CDCl3): 100.83 and 100.8 (OCH2O), 133.2 (C-
1), 134.1 (C-1 ), 108.0 (C-2), 108.1 (C-2 ), 109.15 (C-5),
109.3 (C-5 ), 121.7 (C-6), 121.3 (C-6 ), 147.6 (C-3), 147.5
(C-3 ), 145.8 (C-4), 145.7 (C-4 ), 38.4 (C-7), 39.1 (C-7 ),
52.2 (C-8), 45.8 (C-8 ), 103.3 (C-9), and 72.6 (C-9 ).
2.4. Test Organisms. M. tuberculosis strains H37Rv (ATCC
27294), four monoresistant variants of M. tuberculosis H3Rv,
including isoniazid-resistant (ATCC 35822), streptomycin-
resistant (ATCC 35820), rifampicin-resistant (ATCC 35838),
and ethambutol-resistant (ATCC 35798), and two MDR
clinical isolates of M. tuberculosis (CIBIN/UMF15:99 and
SIN 4) were employed as mycobacterium testing organisms.
M. tuberculosis H37Rv is sensitive to all ﬁve ﬁrst-line anti-
tuberculosis drugs (isoniazid, rifampicin, ethambutol, strep-
tomycin, and pyrazinamide), and the two clinical isolates
were MDR and resistant to all ﬁve ﬁrst-line antituberculosis
drugs. Entamoeba histolytica strain HM1-IMSS and Giardia
lamblia strain IMSS:0989:1 were used as antiprotozoal
testing organisms.
2.5. Antimycobacterial Activity. The Hex extract and pure
compounds were tested using microplate Alamar blue assay
(MABA), as previously described [9, 10]. All assays were
carried out in triplicate, and isoniazid (0.06μgmL −1,S i g m a )
and rifampicin (0.062μgmL −1, Sigma) were included as
positive control drugs to H37Rv-sensitive strains. For MDR




reported as the Minimal Inhibitory Concentration (MIC).
2.6. Antiprotozoal Activity. E. histolytica strain HM1-IMSS
was cultured in a TYI-S-33-modiﬁed medium supplemented
with 10% calf serum, and G. lamblia strain IMSS:0989: 1
was maintained in a TYI-S-33 medium supplemented with
10% calf serum and bovine bile. In vitro susceptibility
assays for both strains were performed by using the method
previously described [11, 12]. Brieﬂy, 5 × 104 tropho-
zoites of G. lamblia were incubated for 48h at 37◦Cw i t h
increasing concentrations of the Hex extract of A. elegans
and the puriﬁed compounds. After incubation, G. lamblia
trophozoites were washed and subcultured for an additional
48h in fresh medium alone. For E. histolytica, 6 × 103
trophozoites were incubated for 72h at 37◦C with increasing
concentrations of the samples tested. Dimethyl sulfoxide
(DMSO) was used as a suitable solvent. Albendazole and
metronidazole were included as positive controls; parasites
without treatment were included as a negative control. G.
lamblia and E. histolytica trophozoites were counted, and the
50% Inhibitory Concentration (IC50) was calculated by Pro-
bit analysis. Experiments were carried out in triplicate and
repeated at least twice. Eupomatenoid-1 was also evaluated
against Trichomonas vaginalis strain GT9 following the same
procedure as for E. histolytica.
3. Results
3.1. Chemical Characterizationof the Puriﬁed Compounds. In
this study, we describe the isolation of eupomatenoid-1 (1),
fargesin (2), and (8R,8 R,9R)-cubebin (3) (Figure 1)f r o m
the Hex extract of A. elegans rhizomes by chemical fraction-
ation on CC. Their structures were elucidated according to
1H-NMR, 13C-NMR, and MS data and were in agreement
withthosepreviouslydescribedintheliterature.IntheHPLC
analysis, the eupomatenoid-1 showed an Rt = 13.09min.
using acetonitrile/formic acid 98:2 system, while fargesin
and (8R,8 R,9R)-cubebin showed Rt = 13.52 and 14.85min.,
respectively, when MeOH was employed; all compounds
were detected at 220 and 280nm.
3.2. Antimycobacterial and Antiprotozoal Evaluation. The
antimycobacterial activity of the Hex extract and puriﬁed
compounds determined by the MABA is depicted in Table 1.
Although Hex extract and eupomatenoid-1 were inactive
againstM.tuberculosisH37Rv(MIC>100μgmL −1),fargesin
and (8R,8 R,9R)-cubebin exhibited good activity against this
strain (MIC = 50μgmL −1). It is noteworthy that the Hex
extract and compound 3 were active against the two MDR
M.tuberculosisclinicalisolates:CIBIN/UMF15:99,andSIN4
(MIC = 50μgmL −1), while compound 2 inhibited only the
growthofSIN4(MIC =50μgmL −1).Inaddition,compound
2 was the most active against the monoresistant variants
of M. tuberculosis H37Rv (MIC = 12.5–25μgmL −1)w i t h
the exception of the ethambutol-resistant strain (MIC >
50μgmL −1). Compounds 1 and 3 were moderately active
against all monoresistant strains of M. tuberculosis H37Rv
tested (MIC = 100μgmL −1).
The antiprotozoal activity of the Hex extract and of pure
compounds 1–3 was tested against the anaerobic protozoa
E. histolytica and G. lamblia (Table 1). It was observed
that the Hex extract was active against these two parasites,
exhibiting IC50 = 0.235 and 0.315μgmL −1,r e s p e c t i v e l y .O n


































Figure 1: Chemical structures of isolated compounds from A. ele-
gans hexanic extract.
against E. histolytica and G. lamblia, achieving IC50 values of
0.624 and 0.545μgmL −1, respectively. Compounds 2 and 3
demonstrated moderate antiprotozoal activity with IC50 <
275.00μgmL −1 against both parasites. Because of its impor-
tant antiprotozoal activity, eupomatenoid-1 was evaluated
against T. vaginalis, showing an IC50 = 0.840μgmL −1.
4. Discussion
The presence of the lignans and neolignans in A. elegans has
been described [2, 5]; however, in this study the presence
of eupomatenoid-1 (neolignan), fargesin, and (8R,8 R,9R)-
cubebin (lignans) has been described for the ﬁrst time in
A. elegans rhizome. In this work, the analytical conditions
that can be employed for detecting these compounds are also
described.
Compound 1 has previously been isolated from Eupo-
matia laurina, A. taliscana,a n dCaryodaphnosis baviensis,
and a related compound, such as eupomatenoid-7, has
been found in A. taliscana [13–17]. Compound 2 has been
isolated from Horsﬁeldia iryaghedhi (Myristica horsﬁeldia),
Piper sarmentosum, Magnolia biondii, Stauranthus perfora-
tus,a n dAristolochia malmeana [18–23]. Compound 3 has
been isolated from related species such as A. legasiana, A.
malmeana, A. odoratissima,a n dA. pubescens [21, 22, 24]. In
fact, structurally similar compounds such as aristelegin A-C
have been reported for the roots and stems of A. elegans [5].
Of the three pure compounds, fargesin (2) was the most
active against the mycobacterium strains tested (MIC <
50μgmL −1); compound 3 showed activity against M. tuber-
culosis H37Rv and two MDR strains of M. tuberculosis.
Eupomatenoid-1 (1) was slightly active against M. tuberculo-
sisH37Rv,itsmonoresistantvariantsandtwoMDRM.tuber-
culosis clinical isolates, in comparison with eupomatenoid-7,
a compound structurally similar to eupomatenoid-1, that we
have previously demonstrated to be more active against the
same strains with MIC values <25μgmL −1 [16]. These data
suggestthatthemethylenedioxygroupintheeupomatenoid-
1 molecule exerts a negative inﬂuence on its antimycobac-
terial activity, since eupomatenoid-7 does not possess this
g r o u pa n dw a sm o r ea c t i v ea g a i n s ts e v e r a lm y c o b a c t e r i u m
strains; nevertheless, further structure-activity studies are
needed to conﬁrm this hypothesis.
It is noteworthy that fargesin was active against M.
tuberculosis H37Rv, its monoresistant strains, and to a lesser
degree against the MDR SIN4 isolate (MIC < 50μgmL −1);
on the other hand some related compounds such as (+)-
sesamin and horsﬁeldin (isolated from Piper sarmentosum)
were inactive against the M. tuberculosis H37Rv strain
(MIC > 200μgmL −1)[ 25]. The bacteriostatic activity of
(8R,8 R,9R)-cubebin has been reported against Streptococcus
mitis, Enterococcus faecalis, Ostrinia nubilalis, and Anticarsia
gemmatalis[21,24–27].Interestingly,inthisstudyithasbeen
demonstrated that compound 3 was active against the two
MDR M. tuberculosis clinical isolates tested showing a MIC
value of 50μgmL −1. Our data suggest that compounds 2
and 3 are two of the possible compounds responsible for the
antimycobacterial activity exerted by the Hex extract of A.
elegans-rhizome.
Current tuberculosis chemotherapy is prolonged (24
months), poorly eﬀective, expensive, and is accompanied
by severe side eﬀects. Besides, the presence of MDR M.
tuberculosis cases is rapidly increasing. MDR accounts for
5.3% of all TB cases reported around the world [28, 29],
underlining the importance of using new alternatives in the
treatment of tuberculosis. In this regard, medicinal plants
have proven to be an important source of antimycobacterial
compounds [28, 30–32]. In fact, it was demonstrated that
puriﬁed compounds 2 and 3 showed signiﬁcant activity
against monoresistant and MDR M. tuberculosis strains.
A murine model of tuberculosis previously developed
by Hern´ andez-Pando et al. [33] could be further used toEvidence-Based Complementary and Alternative Medicine 5
Table 1: Antimycobacterial and antiprotozoal activities of the hexanic extract and pure compounds isolated from A. elegans.
Sample
MIC (μgmL −1) M. tuberculosis IC50 (μgmL −1)
H37Rv CIBIN/UMF15:99 SIN4 RIF-R STR-R INH-R EMB-R E. histolytica G. lamblia
Hexanic extract >100 50 50 ND ND ND ND 0.235 0.315
Eupomatenoid-1 100 100 100 100 100 100 100 0.624 0.545
Fargesin 50 >100 50 25 25 12.5 >50 120.6 262.7
(8R,8 R,9R)-Cubebin 50 50 50 100 100 100 100 137.3 275.0
Rifampicin 0.06 >100 100 >25 0.06 0.06 0.06 — —
Isoniazid 0.06 3.1 3.1 0.06 0.06 >25 0.06 — —
Streptomycin 0.5 >100 >40 . 5>80 . 50 . 5 — —
Ethambutol 2.0 8 >16 1.0 1.0 1.0 >32 — —
Oﬂoxacin — 0.5 8.0 — — — — — —
Metronidazole — — ————— 0 . 0 6 0 0 . 2 1 0
H37Rv: sensitive strain to INH, RIF, EMB, STR, and pyrazinamide; CIBIN/UMF15:99: resistant strain to INH, RIF, EMB, STR, and pyrazinamide; SIN4:
resistant strain to INH, RIF, EMB, STR, rifabutin, ethionamide, and oﬂoxacin; RIF-R: rifampicin-resistant; STR-R: streptomycin-resistant; INH-R: isoniazid-
resistant and EMB-R: ethambutol-resistant. ND: no determined; MIC: minimum inhibitory concentration; IC50: 50% inhibitory concentration. Data are
means of three determinations.
determine the in vivo activity of compounds 2 and 3, result-
ing in insights concerning their potential as antitubercular
agents. On the other hand, the chemical structure of these
compounds can be a prototype for the design and syn-
thesis of new derivatives with enhanced antimycobacterial
activity.
G. lamblia and E. histolytica are two of the most clin-
ically important anaerobic protozoa that cause diarrheal
disease worldwide. Recently, giardiasis was included in the
“Neglected Disease Initiative”, estimating that 280 million
people areinfectedeach yearwithG. lamblia [34]. Therefore,
this stimulated our interest in determining the potential
activity of the Hex extract of A. elegans-rhizome and its
puriﬁed compounds against these two protozoa. Metronida-
zole was included as a reference drug because it has been
regarded as the choice drug for the treatment of giardiasis
and amoebiasis, although it is not always eﬀective and has
severe side eﬀects.
The Hex extract and eupomatenoid-1 were the most
active against both E. histolytica and G. lamblia. It should
be mentioned that metronidazole was just 1.4 and 4 times
more potent than the Hex extract and 2.5 and 10 times more
active than eupomatenoid-1, respectively. The antiprotozoal
activity of eupomatenoid-1 needs to be supported by a
demonstration of its eﬃcacy in animal models as well as by a
clear understanding of its action mechanisms.
Several studies supporting the use of natural products
and their puriﬁed active compounds are an alternative treat-
ment for gastrointestinal infections. In particular, the an-
tiprotozoal activity of Helianthemum glomeratum Lag. and
Rubus coriifolius Focke was demonstrated in vitro and in
vivo [35, 36]. The in vitro activity of MeOH extract from
H. glomeratum and R. coriifolius showed IC50 = 62.92 and
77.82μgmL −1 against G. lamblia; in addition, in a mouse
model of giardiasis, these extracts showed an ED50 =
0.125 and 0.506mgkg−1,r e s p e c t i v e l y[ 36]. The most active
compound isolated from these plants was (−)-epicatechin,
thiscompoundshowedaninvitroIC50 =1.6μgmL −1 against
G. lamblia and in a mouse model of giardiasis had an ED50 =
0.072μmolkg−1.
The inappropriate short-term exposure and exposure
to sublethal levels of metronidazole have induced parasite
drug resistance. Eupomatenoid-1 may therefore be consid-
ered as an active principle or even a prototype molecule
forthedevelopmentofnovelantiprotozoalagentswithactiv-
ity against metronidazole resistant parasites.
5. Conclusion
In this study, the activity of (8R,8 R,9R)-cubebin and far-
gesin, puriﬁed from the Hex extract of A. elegans-rhizome,
was demonstrated against M. tuberculosis H37Rv, four mon-
oresistantvariants,andtwoMDRM.tuberculosisclinicaliso-
lates. Although eupomatenoid-1 showed poor antimycobac-
terial activity, it had signiﬁcant antiprotozoal activity. These
active compounds can be prototype molecules for the design
and synthesis of new derivatives with enhanced antimy-
cobacterial or antiprotozoal activity.
Is currently being evaluated, the acute and subacute tox-
icity of active compounds in a mouse model. Further in vivo
studies may well support the antimycobacterial and antipro-
tozoal activities of A. elegans-rhizome puriﬁed compounds.
The antiprotozoal activity of neolignans and lignans has
scarcely been described in the literature, and our results en-
courage further studies on this issue.
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